2 unknown. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 3 | 2 | Unknown 2 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Hetrombopag, Stanozolol Tablets - MDS | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 50 | 2021-10-01 | 2021-09-24 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
Frailty (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (1) · Stanozolol (1) · Tretinoin (1) · hetrombopag (1)
Peking Union Medical College Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (2)
Bing Han, Docter (1) · Han Yue, Ph.D (1)